Business, energy, technology, markets and global industry news from Business News Today

Helus Pharma

PharmaDeviceNews Helus Pharma
Helus Pharma’s HLP003 moves closer to a pivotal Phase 3 depression data readout after the APPROACH study completed enrolment ahead of schedule. Representative image.
Pharma & Biotech

Helus Pharma finished Phase 3 enrolment early, but HLP003’s decisive test is still ahead

Helus Pharma completes APPROACH enrolment as HLP003 heads toward a pivotal Phase 3 depression data readout in the fourth quarter of 2026.

Read More
Eli Lilly’s up to US$3.8 billion AtaiBeckley deal raises interest in BPL-003 and the expanding psychedelic medicine pipeline. Representative image.
Pharma & Biotech

Eli Lilly’s psychedelic deal carries a US$3.8bn headline, but the fine print tells the real story

Eli Lilly’s AtaiBeckley deal brings psychedelic medicine into big pharma’s M&A race, but Phase 3 data and rescheduling still decide its value.

Read More